ArticleInternational journal of pharmaceutics2012
Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system.
Article in International journal of pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 93 citations in OpenAlex.
- From barrier to guide: Exploiting disease-specific hemodynamics for enhanced nanodrug targeting in cardiovascular diseases.Pharmaceutical science advances · 2026Review
- Therapeutic Effects of Nanoparticles Loaded with Combined Sense and Anti-Sense of EpoR Plasmids to Enhance Angiogenesis.Research square · 2026Article
- Platelet-derived biomimetic nanoplatforms: a promising drug delivery strategy for cardiovascular disease.Journal of nanobiotechnology · 2025Review
- Potential of Platelet-Based Drug Delivery System for Treating Peritoneal Metastasis of Gastric Cancer.Cancer science · 2025Article
- Cell-Based Drug Delivery Systems: Innovative Drug Transporters for Targeted Therapy.International journal of molecular sciences · 2025Review
- Experimental studies on squeezing interstitial fluid via transfer of ultrasound momentum (SIF-TUM) inJournal of applied physics · 2025Article
- Nanoparticle-Based Drug Delivery for Vascular Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles.Bioactive materials · 2024Article
- Review
- Nanoparticle-based approaches for treating restenosis after vascular injury.Frontiers in pharmacology · 2024Review
- Multiscale physics-basedFrontiers in drug delivery · 2024Review
- Targeted Nanoparticles for the Binding of Injured Vascular Endothelium after Percutaneous Coronary Intervention.Molecules (Basel, Switzerland) · 2022Article
- Influence of Elasticity of Hydrogel Nanoparticles on Their Tumor Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A Review of Functional Analysis of Endothelial Cells in Flow Chambers.Journal of functional biomaterials · 2022Review
- Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis.Journal of nanobiotechnology · 2022Review
- Platelet-inspired therapeutics: current status, limitations, clinical implications, and future potential.Drug delivery and translational research · 2021Review
- Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction.International journal of nanomedicine · 2021Review
- Targeting Selectins Mediated Biological Activities With Multivalent Probes.Frontiers in chemistry · 2021Review
- Therapeutic Potential of Polyphenols-Loaded Polymeric Nanoparticles in Cardiovascular System.Molecules (Basel, Switzerland) · 2020Review
- Effect of Flow-Induced Shear Stress in Nanomaterial Uptake by Cells: Focus on Targeted Anti-Cancer Therapy.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
This research aims to develop targeted nanoparticles as drug carriers to the injured arterial wall under fluid shear stress by mimicking the natural binding ability of platelets via interactions of glycoprotein Ib-alpha (GPIbα) of platelets with P-selectin of damaged endothelial cells (ECs) and/or with von Willebrand factor (vWF) of the subendothelium. Drug-loaded poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles were formulated using a standard emulsion method and conjugated with glycocalicin, the external fraction of platelet GPIbα, via carbodiimide chemistry. Surface-coated and cellular uptake studies in ECs showed that conjugation of PLGA nanoparticles, with GPIb, significantly increased nanoparticle adhesion to P-selectin- and vWF-coated surfaces as well as nanoparticle uptake by activated ECs under fluid shear stresses. In addition, effects of nanoparticle size and shear stress on adhesion efficiency were characterized through parallel flow chamber studies. The observed decrease in bound nanoparticle density with increased particle sizes and shear stresses is also explained through a computational model. Our results demonstrate that the GPIb-conjugated PLGA nanoparticles can be used as a targeted and controlled drug delivery system under flow conditions at the site of vascular injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.